Strategies for Remission Prolongation

Prolonging remission in acute myeloid leukemia (AML) requires strategic approaches, primarily centered around intensive allogeneic stem cell transplantation and maintenance therapies. Achieving a deeper remission through optimized initial therapy is critical, as research indicates that patients who enter transplantation in a deeper state of remission tend to experience better post-transplant outcomes. The choice of pre-transplant chemotherapy, such as CPX-351 or traditional regimens like 7+3, can significantly affect remission depth and impact subsequent treatment strategies. As the discussion highlights, the integration of measurable residual disease (MRD) assays aids in tailoring therapies and identifies candidates who may benefit from intensified or alternative treatments.